Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

This article has no abstract
Epistemonikos ID: d7c609790ed69d470f34b9fd00f4d8673c91fa6c
First added on: Feb 12, 2025